Effects of rTMS on Human Brain Activity Measured With fMRI
NCT ID: NCT03259568
Last Updated: 2023-03-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
27 participants
INTERVENTIONAL
2018-01-12
2019-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of rTMS on Human Brain Activity
NCT04242810
Network Control TMS fMRI
NCT05736458
Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.
NCT03698591
Network-guided TMS in Early Alzheimer's Disease
NCT04549155
rTMS Brain Stimulation and Cognition
NCT04244682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose-response TMS - Intensity = 20%RMT
Four levels of TMS intensity (here, 20% of Resting Motor Threshold), titrated to each individual, tested within the MRI.
Outcome measures include accuracy, RT, and BOLD signal.
Repetitive TMS
1-10 Hertz rTMS will be administered
Dose-response TMS - Intensity = 40%RMT
Four levels of TMS intensity (here, 40% of Resting Motor Threshold), titrated to each individual, tested within the MRI.
Outcome measures include accuracy, RT, and BOLD signal.
Repetitive TMS
1-10 Hertz rTMS will be administered
Dose-response TMS - Intensity = 80%RMT
Four levels of TMS intensity (here, 80% of Resting Motor Threshold), titrated to each individual, tested within the MRI.
Outcome measures include accuracy, RT, and BOLD signal.
Repetitive TMS
1-10 Hertz rTMS will be administered
Dose-response TMS - Intensity = 120%RMT
Four levels of TMS intensity (here, 120% of Resting Motor Threshold), titrated to each individual, tested within the MRI.
Outcome measures include accuracy, RT, and BOLD signal.
Repetitive TMS
1-10 Hertz rTMS will be administered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive TMS
1-10 Hertz rTMS will be administered
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Use of effective method of birth control for women of childbearing capacity.
3. Willing to provide informed consent.
Exclusion Criteria
2. Current serious medical illness (self report).
3. History of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator); \[TMS Adult Safety Screening (TASS) form\].
4. Subjects are unable or unwilling to give informed consent.
5. Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV)
6. Subjects with a clinically defined neurological disorder including, but not limited to:
1. Any condition likely to be associated with increased intracranial pressure
2. Space occupying brain lesion.
3. History of stroke.
4. Transient ischemic attack within two years.
5. Cerebral aneurysm.
6. Dementia.
7. Mini Mental Status Exam (MMSE) score of \<24.
8. Parkinson's disease.
9. Huntington's disease.
i. Multiple sclerosis.
7. Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold.
8. Subjects with cochlear implants
9. Subjects not willing to tolerate the confinement associated with being in the MRI scanner.
10. Women who are pregnant or breast-feeding (urine test).
11. Blindness.
12. Inability to read or understand English.
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00082433
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.